Panel Discussion: AMP Working Group: Tumor Mutational Burden Assay Validation and Reporting

Thursday, November 16, 2023

3:00 PM - 3:30 PM MST

Panelist(s)

Larissa V. Furtado, MD

Associate Member
St. Jude Children’s Research Hospital
Memphis, Tennessee, United States
Susan Hsiao, MD, PhD

Associate Professor of Pathology and Cell Biology
Columbia University Medical Center
New York, New York, United States
Jonathan A. Nowak, MD, PhD

Pathologist
Brigham and Women's Hospital
Boston, Massachusetts, United States

Session Description: Tumor mutational burden (TMB) is a biomarker that can predict response to immunotherapy. Many laboratories are offering TMB testing, but there is variation in how TMB is calculated, reported, and interpreted among laboratories. While TMB standardization efforts are underway, no published guidance for TMB validation and reporting is currently available. To address these challenges, the Association for Molecular Pathology has convened a multidisciplinary collaborative working group with representation from the American Society of Clinical Oncology, College of American Pathologists, and Society for the Immunotherapy of Cancer to review the laboratory practices surrounding TMB and develop recommendations for the analytical validation and reporting of TMB testing..

Learning Objectives:

Discuss literature review findings and new draft recommendations for TMB assay validation and test reporting.
Discuss new draft recommendations and their impact on clinical practice.